MENLO PARK, Calif.--(BUSINESS WIRE)--Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it is beginning shipments of its porcine and human insulin assay. The assay has many advantages over existing technologies, significantly improving productivity. Initial users are measuring secreted and total content of both porcine and human islet cells for research and transplantation trials seeking a cure for Type I diabetes.
